DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR EWING’S SARCOMA

DIAGNOSTICS
Highly specific gene-based biomarker for the diagnosis of Ewing’s sarcoma.

TECHNOLOGY TYPE
Biomarkers
Therapeutics
Oncology
Ewing’s Sarcoma

STAGE OF DEVELOPMENT
- Tests showing sensitivity and specificity of NKX2.2 for Ewing’s sarcoma underway.
- Ongoing work to study potential NKX2.2 inhibitors.

IP PROTECTION
U.S. Utility Patent Issued
Methods and Compositions for the Diagnosis and Treatment of Ewing’s Sarcoma
US7939253B2

FEATURES AND BENEFITS
- Early biomarker for detection of Ewing’s sarcoma.
- Rapid and sensitive qPCR-based test.
- Can be added to other gene panels for multiplex testing for other biomarkers or cancer types.

RECENT PUBLICATIONS
doi: 10.18632/genesandcancer.57

INVENTOR PROFILE
Stephen Lessnick, M.D., Ph.D., Assistant Professor - Oncology